Jasper-Kira merger resets the clock with $132M and a three-program pipeline, but briquilimab's pre-BLA path in SCID must validate before KP-104's Phase 3 case is built

Bull

FDA confirms an acceptable regulatory pathway at the pre-BLA meeting, aligning on the existing long-term SCID dataset as sufficient to support a BLA submission without additional trials. This would trigger progress toward a BLA filing, likely generation of a priority review voucher worth tens of millions of dollars upon approval, and would validate the core rationale for the Jasper-Kira merger — demonstrating the combined company has a near-term approval catalyst anchoring its pipeline.

Bear

The FDA requests additional clinical data, a new controlled trial, or raises chemistry/manufacturing concerns that extend the timeline materially beyond current projections. Given that SCID is a rare pediatric indication with small patient populations, enrollment of any additional study would be slow and capital-intensive; with runway guided through H2 2028, a meaningful regulatory setback could force another financing before the BLA is filed, diluting shareholders and undermining the thesis.